Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations

Hossain et al offer a clinical practice guideline for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). An evidence-based guideline for the treatment of patients with SSc-ILD was created in 2023 by a panel of multidisciplinary experts. Systematic literature reviews...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the American Thoracic Society 2024-01, Vol.21 (1), p.12-16
Hauptverfasser: Hossain, Tanzib, Montesi, Sydney B, Volkmann, Elizabeth R, Thomson, Carey C, Ruminjo, Joseph K, Silver, Richard M, Ghazipura, Marya, Raghu, Ganesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hossain et al offer a clinical practice guideline for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). An evidence-based guideline for the treatment of patients with SSc-ILD was created in 2023 by a panel of multidisciplinary experts. Systematic literature reviews were performed for the following therapies: cyclophosphamide, mycophenolate, rituximab, tocilizumab, nintedanib, combination of nintedanib plus mycophenolate, pirfenidone, and combination of pirfenidone plus mycophenolate. Interstitial lung disease frequently complicates SSc, resulting in increased morbidity and mortality. SSc-ILD is the most common cause of SSc-related death.
ISSN:2329-6933
2325-6621
DOI:10.1513/AnnalsATS.202309-760CME